Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RECQL | P46063 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773565 | 1.00 | CYP1A2 (0.48) | CYP1A2KDM4EMAPTLMNAMEN1 | |
| SCHEMBL3335156 | 0.80 | MAPT (0.48) | CYP1A2KDM4EMAPTLMNAMEN1 | |
| Gw305178X SCHEMBL29636843 | 0.78 | EIF2AK2 (0.46) | CYP1A2MAPTALDH1A1 | |
| Gw305178X SCHEMBL5894133 | 0.78 | EIF2AK2 (0.46) | CYP1A2MAPTALDH1A1 | |
| Gw305178X SCHEMBL5894138 | 0.78 | EIF2AK2 (0.46) | CYP1A2MAPTALDH1A1 | |
| SCHEMBL5893988 | 0.72 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL5893985 | 0.72 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL6610170 | 0.71 | SMN1; SMN2 (0.48) | CYP1A2KDM4EMAPTLMNAMEN1 | |
| SCHEMBL6610179 | 0.71 | SMN1; SMN2 (0.48) | CYP1A2KDM4EMAPTLMNAMEN1 | |
| SCHEMBL7658852 | 0.68 | KDM4E (0.48) | CYP1A2KDM4EMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1313732-B1 | OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6720332-B2 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20030195189-A1 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | disclosed |
| EP-1313732-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | CYP1A2 3988/4885KDM4E 960/4885MAPT 2084/4885 |
| US-20030195189-A1 | Oxindole derivatives | CDK4, CCNI, CCNO | CYP1A2 1719/4885KDM4E 1346/4885MAPT 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.